Leading Azerbaijani Physician Presents Definitive COVID-19 Volume at Cambridge University

The historic halls of St Catharine's College, Cambridge University, welcomed the official U.K. launch of COVID-19: Disease of the Century, the groundbreaking new book by Prof. Lala Allahverdiyeva, Honoured Doctor of Azerbaijan and Head of Clinical Allergology & Immunology at Azerbaijan Medical University (AMU).

Senior British and international academics, clinicians, students, representatives of several learned societies, and officials from the Embassy of Azerbaijan in the United Kingdom were in attendance. Their presence underlined Cambridge's status as a global center for medical innovation and the significance of Prof. Allahverdiyeva's contribution to the pandemic discourse.

"Presenting this work within the storied walls of Cambridge is both a professional honor and a global call to action," Prof. Allahverdiyeva told the gathering. "The lessons we draw from COVID-19 will shape the next century of medicine. I hope this book equips decision-makers with the multidisciplinary insight the moment demands."

Prof. Allahverdiyeva answered the audience's questions, demonstrated her professional ability to tackle the complex attributes of post-COVID syndrome, and addressed the need to be ready for the pandemic. Following the book presentation at Ramsden Room of St Catharine's College, Cambridge University, Prof. Allahverdiyeva was at the center of multiple discussions.

Prof. Nikolaos Tzenios, Senior Vice-President of the World Academy of Medical Sciences, introduced Prof. Allahverdiyeva to the Cambridge audience of academics, professors, students, and other dignitaries and attendees of the special event. He praised Prof. Allahverdiyeva for "the thousands of lives saved through her work during and after the pandemic". He highlighted Azerbaijan Medical University's rising global profile in medical education and research.

"Prof. Allahverdiyeva exemplifies how sound governance and visionary leadership in Azerbaijan have fostered scientific excellence with worldwide impact. We all admire the Impact of the immense investment of the Azerbaijani wise and active leadership in building Baku as an architectural marvel of the Caspian-Asia-Europe region and the Azeri nation as a beacon of education, research, and science," Prof. Tzenios noted.


A Comprehensive, Cross-Disciplinary Analysis

Spanning 256 pages, 20 chapters, and 193 peer-reviewed references, COVID-19: Disease of the Century seamlessly weaves virology, public health strategy, and geopolitical context. Key chapters explore:

• Biology of SARS-CoV-2 – molecular structure, mutation dynamics, zoonotic origins
• Comparative Outbreaks – detailed parallels with SARS and MERS epidemics
• Diagnostics & Therapeutics – evidence-based best practices and emerging treatments
• Vaccination Pathways – efficacy data, contraindications, and rollout strategies
• Special Populations – disease course in children and patients with allergic conditions
• Post-COVID Rehabilitation – pioneering speleotherapy results from Azerbaijan's Duzdag Caves


Speleotherapy Spotlight

During her keynote, Prof. Allahverdiyeva showcased Azerbaijan's innovative use of the Duzdag salt caves (Nakhchivan) for post-COVID rehabilitation. Preliminary clinical results indicate marked respiratory and immunological improvements, positioning the program as a potential model for long-term care worldwide.


About the Author

Prof. Lala Allahverdiyeva, MD, PhD, heads the Department of Clinical Allergology & Immunology at AMU and is an Honoured Doctor of the Republic of Azerbaijan. She has published over 150 scientific papers on respiratory immunopathology, vaccine safety, and novel therapeutics and has served on multiple international advisory boards.

https://wams.online/
https://www.amuuni.com/

Protheragen Announces GeniusAb™: A Fully Human Single-Domain Antibody Platform

New York, United States—Protheragen has launched GeniusAb™, a fully human single-domain antibody platform to produce high quality and customized antibodies for research, diagnostic and therapeutic use. This is a major breakthrough in the field of therapeutic antibodies as it is able to provide highly specific, robust, and versatile solutions to a variety of diseases.

Single-domain antibodies (sdAbs), also known as VHH antibodies or camelid antibodies, are derived from the immune systems of camels and llamas. Unlike conventional antibodies, the unique structure of sdAbs allows them to bind to targets with high affinity and selectivity while maintaining stability and ease of production. These advantages make sdAbs a promising tool in biotechnology and therapeutics.

To reduce the costs and time involved in identifying new therapeutic single-domain antibodies from species such as camels and sharks, Protheragen has found a way to do so: the GeniusAb™ mice. These genetically engineered mice are designed to produce fully human single-domain antibodies. By leveraging these mice, researchers can avoid the need for in vitro humanization, leading to a more streamlined and economical process.

Protheragen’s GeniusAb™ mouse model boasts several advantages, including:

Robust immune responses to diverse antigens: The GeniusAb™ mouse models have a rich repertoire of B cells capable of recognizing and responding to different antigens, including proteins, peptides, and pathogens.

Sequence diversity and optimal affinity: By incorporating human antibody gene segments and implementing genetic modifications, GeniusAb™ mice exhibit a variety of antibody sequences that closely mimic those present in humans, which can enable the examination of a wide array of antibody variants and enhance the likelihood of discovering antibodies with ideal affinity and specificity for the desired target.

Excellent developability: Antibodies produced from GeniusAb™ mice possess advantageous traits, including stability, solubility, low immunogenicity, and compatibility with subsequent manufacturing processes, paving the way for the development and commercialization of antibody-based therapeutics and diagnostics.

The GeniusAb™ platform harnesses the unique properties of single-domain antibodies while ensuring that they are entirely compatible with the human immune system. This innovation opens new avenues for drug discovery and development, allowing researchers to tackle previously challenging targets with unmatched precision and efficacy.

About Protheragen

Protheragen GeniusAb™ focuses on fully human single-domain antibodies. Leveraging cutting-edge fully human single-domain antibody platforms and advanced antibody screening platforms, Protheragen offers comprehensive and seamless solutions for antibody preparation and screening.

bottom logo

IQ4I Research has published Emerging Isotopes Pipeline Analysis and Global Market

“Emerging Isotopes Pipeline Analysis and Global Market – Forecast to 2029” gives comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications. The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).

In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.

  • Market Analysis
  • In market analysis, global GEP-NET, Prostate cancer and Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177 therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2021 to 2029.
  • Emerging Isotopes related deals analysis.
  • Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).
  • Pipeline Analysis
  • Pipeline Analysis based Isotopes
  • Pipeline Analysis based on indications
  • Pipeline analysis based on targets
  • Pipeline analysis based on leading players
  • Key Players Analysis
  • The key player’s analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
  • Key players overview
  • Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)
  • Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)

Major players working on the emerging isotopes are Boston Scientific Corp. (U.S.) Clarity Pharmaceuticals (Australia), Curium SAS (France), Eckert & Ziegler (Pentixapharm) (Germany), Fusion Pharmaceuticals (Canada), Novartis International AG (Switzerland), ITM (Isotope Technologies Munich) (Germany), Orano Med, LLC (U.S.), Plus Therapeutics (U.S.), Point Biopharma (U.S.), RadioMedix, Inc. (U.S.) and Telix Pharmaceuticals (Australia).

Please visit our website:https://iq4i.com/reports/emerging-isotopes-pipeline-analysis-and-global-market-forecast-to-2029

write to us: This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: +91-8147030229

GM2 Gangliosidosis drugs are in phase 1 which will boost the market during the forecast period

GM2 Gangliosidosis, often known as Tay-Sachs disease, is caused by a mutation in the HEXA genes, which results in muscular atrophy. Because this disease has no known cure, therapy is mainly symptom-based. Some of the signs and symptoms include exaggerated reactions to loud noises, seizures, loss of movement, vision, and hearing, mucus collection in the lungs, and other symptoms. Tay-Sachs disease is also known as hexosaminidase disease. A deficiency is a rare inherited neurological disease caused by a loss of the enzyme hexosaminidase A, which results in the accumulation of G2 gangliosides.

The report " Global GM2 Gangliosidosis Market, By Type (Infantile, Juvenile and Adult), By Therapeutics (Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy), By Drugs (Anticonvulsant, Antipsychotic medication and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

  • Axovant Sciences, Inc. released clinical data for AXO-AAV-GM2, a gene therapy for Tay-Sachs disease, in March 2019. In a 30-month-old kid with advanced infantile Tay-Sachs disease, the trial showed that it was well tolerated with no significant adverse effects.
  • IntraBio Inc. submitted an Investigational New Drug (IND) application to the FDA in February 2019 for IB1001-202 to treat Tay-Sachs and Sandhoff Disease. The IND approval is a huge step forward for both the patients and the researchers.

Analyst View:

The market's expansion is due to the rising occurrence of genetic disease, particularly among newborns. Additionally, increased investment in R&D activities to develop new treatment options to cure the genetic disorder, as well as the release of new and improved medications to treat the disease's symptoms and consequences, are likely to propel market growth. The industry could be boosted by high demand for disease-specific novel treatments. Market growth is being boosted by the release of drugs to treat GM2 Gangliosidosis-related problems.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global GM2 Gangliosidosis Market, By Type (Infantile, Juvenile and Adult), By Therapeutics (Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy), By Drugs (Anticonvulsant, Antipsychotic medication and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

To know the upcoming trends and insights prevalent in this market, click the link below:

https://www.prophecymarketinsights.com/market_insight/Global-GM2-Gangliosidosis-Market-4727

Key Market Insights from the report:

The Global GM2 Gangliosidosis Market is segmented based on the type, therapeutic, drugs, and region.

  • By Type, the Global GM2 Gangliosidosis Market is segmented into Infantile, Juvenile and Adults.
  • By Therapeutic, the market is segmented in Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy.
  • By Drugs, the Global GM2 Gangliosidosis Market is segmented into Anticonvulsant, Antipsychotic medication and Others.
  • By Region, the Global GM2 Gangliosidosis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. the market in North America is expected to increase significantly.

Competitive Landscape:

The key players operating in the global GM2 Gangliosidosis market includes Pfizer, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca, Novartis AG, and others. Recursion Pharmaceuticals, Inc., IntraBio Inc., Johnson & Johnson Services, Inc., and Axovant Sciences, Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Some Important Points Answered in this Market Report Are Given Below:

  • Explains an overview of the product portfolio, including product development, planning, and positioning.
  • Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
  • Detailed analysis of the market revenue over the forecasted period.
  • Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
  • Study on the segments that are anticipated to dominate the market.
  • Study on the regional analysis that is expected to register the highest growth over the forecast period. 

Key Topics Covered

  1. Introduction
  • Study Deliverables
  • Study Assumptions
  • Scope of the Study
  1. Research Methodology
  2. Executive Summary
  • Opportunity Map Analysis
  • Market at Glance
  • Market Share (%) and BPS Analysis, by Region
  • Competitive Landscape
  • Heat Map Analysis 
  • Market Presence and Specificity Analysis
  1. Investment Analysis
  2. Competitive Analysis

To know more

Contact Us:

Sales

Prophecy Market Insights

  1 860 531 2701

Email- This email address is being protected from spambots. You need JavaScript enabled to view it.

Hetero Healthcare Set to Supply COVID19 Drug Remdesivir Under Brand Name COVIFOR

 Hetero’s group company ‘Hetero Healthcare Limited’ is all set to supply 20,000 vials of Covifor(Remdesivir) across the country.


Hyderabad, India;
24th June 2020: Following the approval of ‘COVIFOR’, the generic of Remdesivir by DCGI, Hetero Healthcare Limited, a group company of Hetero is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which, will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra; while the other lot will be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week’s time, in order to meet the emergency requirements.

Mr. M. Srinivasa Reddy, Managing Director, Hetero Healthcare Limited said: “The launch of COVIFOR in India is a significant milestone for all of us. Hetero Healthcare has always been at the forefront in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital, thereby reducing the increasing pressure on the medical infrastructure, overburdened currently due to accelerating COVID-19 infection rates. We are working closely with the Government and Medical Community to make ‘Covifor’ quickly accessible to both public and private healthcare settings across the country.”

Covifor is the first generic brand of Remdesivir which is indicated for the treatment of COVID-19 patients in adults and children, hospitalized with severe symptoms of the disease. The drug is available in 100 mg vial (Injectable). It needs to be administered intravenously in a hospital, critical care setting, under the supervision of a registered medical practitioner. Covifor is anticipated to play a significant role in bringing down the mortality rates caused by COVID-19, given its proven positive clinical outcomes.

 

About Hetero Healthcare

Established in 1994, Hetero Healthcare Limited is a group company of Hetero which is engaged in the marketing and distribution of medicines in the Indian market. The company has a strong presence in India with 11 specialized marketing divisions and has been a market leader in ARV, Oncology, anti-flu anti-bacterial. With the team of 3200+ field force, Hetero Healthcare caters to medical practitioners in over 400 territories across India.

For Enquiries

  • Visit http://www.heterohealthcare.com/covifor-100mg-injection
  • Hospitals can place their orders by sending an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Patients can reach out to Hetero Healthcare Team either through toll-free no.: 1800 1034 696 or through WhatsApp on +91 9320985814
Page 1 of 2